MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Interventional Oncology: Fast Forward to the Future
The field is at a crossroads where opportunities must be seized to establish a permanent foothold in the crowded world of oncology care.
By Jean-Francois H. Geschwind, MD
Lipiodol Evaluated as an Imaging Biomarker of Tumor Response After cTACE
April 16, 2020—Findings from a single-center, single-arm study support the use of Lipiodol (Guerbet LLC) as an imaging biomarker of tumor response after conventional transarterial chemoembolization (cTACE) for both primary and secondary liver cancer.
Emerging Trends in Interventional Oncology
By Ripal T. Gandhi, MD, FSIR, FSVM, and David M. Liu, MD, FRCPC, FSIR
Combining Antiangiogenesis Treatment and Chemoembolization
A new approach for managing hepatocellular carcinoma.
By Eleni Liapi, MD, and Jean-Francois Geschwind, MD
CHIEF MEDICAL EDITOR'S PAGE: Continued Progress in Embolization
By Jafar Golzarian, MD
